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Medi-Cal data were available on an 11-year time span
(July 1985–December 1996). Only the first episode of
treatment for each patient was considered. Patients were
further excluded if they were pregnant, they were in long-
term facilities before and at the keydate, and if they lost
their Medi-Cal eligibility during the study period.
RESULTS: In this study 30,200 patients met the eligibility
criteria (mean age 60.8  19.4, 67.1% female). Among
patients, 20.8% started their therapy with a calcium-
channel-blocker, 18.7% with a diuretic, and 18.6% with
a beta-blocker. Before the end of the study period, 94.2%
of patients either discontinued or interrupted their anti-
hypertensive medications. Average cost in the post-period
(e.g., hospital, ambulatory care, and all other costs but
prescription and long-term care) was $7945 for discon-
tinuing versus $7525 for continuing patients (Wilcoxon-
rank-sums test, p  0.0354).
CONCLUSIONS: Patients who interrupt their anti-
hypertensive medications cause a higher healthcare ex-
penditure than continuous patients. Further analyses are
needed considering co-factors that may influence health-
care utilization.
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THE ROLE OF ALTERNATIVE 
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Shi L, Nichol MB
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OBJECTIVE: To compare the effects of hydroxymethyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) with non-statins on compliance duration, health-
care utilization, and healthcare costs in an health mainte-
nance organization (HMO) population.
METHODS: A retrospective cohort study was performed
using claims data and survey data in continuously en-
rolled patients (n  810) with prescriptions for antihy-
perlipidemic medications from April 1993 to March
1995. Compliance duration was defined as the duration
of over 80% compliance with antihyperlipidemic medica-
tions, healthcare utilization measures as hospital admis-
sions due to cardiac diseases and outpatient visits, and
healthcare cost variables as total healthcare costs, net
costs, and drug cost. Each main outcome measure was
modeled (Tobit model for compliance duration, probit
model for healthcare utilization, and OLS model for
healthcare costs).
RESULTS: The statins significantly prolonged the com-
pliance duration (p  0.05). The factors significantly in-
fluencing on compliance duration were female gender,
baseline high compliance, chronic disease scores, number
of cholesterol-lowering drugs in the regimen, and diag-
nostic characteristics such as peripheral vascular diseases
(PVD), cardiac diseases (CVD), hypertension, and diabe-
tes. The statins significantly decreased adjusted hospital
admissions due to CVD in year 1 (p  0.05) especially in
those patients with PVD (p  0.01) and CVD (p  0.05).
There was no significant difference in total healthcare
costs in year 1 between patients on statins and those on
non-statins. However, in year 2 and pooled data (year 1
and year 2), the statins were significantly associated with
higher total healthcare costs (p  0.05, p-pooled  0.05)
and higher drug costs (p  0.0001, p-pooled  0.0001).
CONCLUSIONS: The statins improved patient’s compli-
ance of antihyperlipidemic therapy. The statins also de-
creased the hospital admissions due to CVD without signif-
icantly elevated healthcare costs in the short term (year 1).
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The ultimate goal of pharmaceutical care is to improve
patient HRQoL. Although researchers have attempted
successfully to link pharmaceutical care behaviors with
HRQoL, the findings are not consistent. Furthermore,
the role of patient satisfaction and compliance in this re-
lationship needs to be explored.
OBJECTIVE: To test a path analytic model depicting the
association of pharmacists’ directive guidance behaviors,
patient satisfaction, compliance, and HRQoL. Pharma-
cists’ directive guidance behaviors were used as an indica-
tor of the level of pharmaceutical care.
METHODS: Five ambulatory care pharmacies/clinics
were selected for study participation. A 50-item question-
naire eliciting information about demographics, percep-
tion about pharmacists’ directive guidance behaviors, sat-
isfaction with pharmaceutical care behaviors, compliance
and HRQoL was administered to volunteers at each
study site. A total of 160 patients completed the ques-
tionnaire.
RESULTS: Bivariate correlations showed that directive
guidance behaviors were significantly correlated to pa-
tient satisfaction (r  0.56, p  0.001), and SF-12 Physi-
cal Component Summary (PCS) and Mental Component
Summary (MCS) scores (r  0.19, p  0.05; r 
0.19, p  0.05, respectively). Also, patient satisfaction
was significantly correlated to PCS (r  0.20, p 
0.05). Compliance was significantly correlated to PCS
(r  0.25, p  0.01) and MCS (r  0.23, p  0.01). Two
path analytic models using PCS and MCS as dependent
variables were tested. In path analysis with PCS as the de-
pendent variable, compliance had significant total causal
effect of 0.16 (p  0.05) that was due to its direct effect.
No other path coefficients were significant in this model.
In path analysis with MCS as the dependent variable, no
path coefficients were significant.
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CONCLUSIONS: In the two path analytic models evalu-
ated, only patient compliance had a significant direct ef-
fect on PCS. Re-specification of the models is needed.
DECISION ANALYTIC MODELING
TPDM1
ASSESSING THE PREDICTIVE ABILITY OF
A DETERMINISTIC MODEL AND 
STOCHASTIC MODEL
Krueger KP1, Cox ER2, Draugalis JR2, Slack MK2
1Auburn University, Auburn, AL, USA; 2University of Arizona, 
Tucson, AZ, USA
Formulary decisions are often based upon the safety, effi-
cacy, and projected costs of medications. Models used to
predict costs are rarely assessed to determine their predic-
tive ability.
OBJECTIVE: The purpose of this study was to assess the
ability of a decision analytic deterministic model and a re-
gression analytic stochastic model to predict the diabetes-
specific costs incurred during the 12 months after met-
formin was added to an HMO formulary. The ability of
the stochastic model to predict total healthcare costs was
also assessed.
METHODS: The deterministic model, a decision tree,
was constructed within an equilibrium framework using
literature-based probabilities and internal costs to predict
diabetes-specific costs. A regression model was con-
structed using medical and pharmacy claims data to pre-
dict diabetes-specific cost and total healthcare costs.
RESULTS: The total diabetes-specific cost estimate pre-
dicted by the decision analytic model came within 5% of ac-
tual costs. The model underestimated the diabetes-specific
medical costs and overestimated the diabetes-specific phar-
macy costs. The diabetes-specific regression model pro-
duced an estimate that was within 18% of the actual costs.
The total healthcare cost model estimate was within 7% of
the actual costs. The total and diabetes-related medical cost
estimates were within 6% and 46% of the actual costs re-
spectively. The total and diabetes-specific pharmacy costs
were within 20% and 49% of the actual costs, respectively.
CONCLUSION: Further research is needed to refine model
construction techniques. A decision tree constructed with
internal data should be used to predict disease-specific costs
when only medical and pharmacy claims data from the pre-
vious year are available, and a regression model should be
used to predict total healthcare costs.
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COST-EFFECTIVENESS OF INCREASING 
WARFARIN USAGE FOR STROKE PROPHYLAXIS 
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In response to mounting pressures to improve stroke pro-
phylaxis for patients with atrial fibrillation, many hospi-
tals and healthcare systems have opened specialty antico-
agulation clinics.
OBJECTIVE: The purpose of this study was to determine
the cost-effectiveness of stroke prophylaxis from a hospi-
tal system perspective.
METHODS: We have developed a decision model repre-
senting several options for stroke prophylaxis. Simulated
patients could receive warfarin through either an anticoag-
ulation clinic or their family physician, aspirin, or no ther-
apy. Possible events were thromboembolic stroke, hemor-
rhagic stroke, hemorrhage requiring hospitalization (major
hemorrhage), or hemorrhage requiring a clinic visit and/or
warfarin dose adjustment (minor hemorrhage). Three dif-
ferent scenarios of stroke prophylaxis are presented: 1) a
healthcare system with an anticoagulation clinic; 2) a sys-
tem which maximizes anticoagulation with warfarin via
the family physician; and 3) a system which maximizes an-
ticoagulation but utilizes anticoagulation clinics to a larger
extent.
RESULTS: Option 1 was the least costly and effective
strategy with a 10-year average cost of $6327/patient
treated and a life expectancy of 7.728 years. The values
for 2 and 3 were $6549 and 7.735 life-years, and $6443
and 7.761 life-years, respectively. The incremental cost-
effectiveness was $34,339/life-year saved for 2 versus 1
and $4013/life-year saved for option 3 versus 1. Option 3
was dominant over 2. These results were sensitive to the
cost per clinic or office visit and the rate of occurrence of
major hemorrhage.
CONCLUSION: Increasing warfarin utilization is cost-
effective from a healthcare system’s perspective. Antico-
agulation clinics appear to be the best method for achiev-
ing this goal.
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IS THERE POTENTIAL BIAS IN MODELING 
WITH DECISION ANALYTIC SOFTWARE OR 
MATRIX PROGRAMMING?
Nichol G, Wells GA
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Decision analytic software is commonly used to estimate
long-term costs or effects of treatment by using Markov
models. Monte Carlo simulation is used to estimate con-
fidence limits (CL) for costs or effects in decision models.
Exact cost or effects may be calculated by matrix inver-
sion. CL for costs and effects may be calculated from ma-
trix inversion by using distributions for each transition
probability.
OBJECTIVES: The objective of this study was to validate
decision analytic software by comparing the bias in deci-
sion analytic CL and matrix CL.
